Navigation Links
Biopure Exploring Strategic Options
Date:2/17/2009

Earnings for year ended October 31, 2008, contained in Annual Report filed on February 13, 2009, with Going Concern Modification

CAMBRIDGE, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it is exploring strategic options for financing or alternative transactions. The company has engaged Newbury Piret & Co. to advise on options, including evaluation of nonbinding proposals that have been received. There should be no assumption that this process will result in any transaction or any particular type of transaction.

On February 13, 2009, the company filed with the SEC its Annual Report on Form 10-K, which contains the company's financial statements for the two years ended October 31, 2008. The company does not intend to issue a separate earnings release. The report of the company's independent registered public accounting firm contained in this filing is modified with respect to the company's ability to continue as a going concern.

Biopure Corporation

Biopure Corporation develops pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the company is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 214,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that any transaction will be entered into to prevent the company from ceasing operations. Actual results may differ materially from those in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, the assessment of third parties of the Company's products and prospects, the Company's ability to negotiate a transaction with acceptable terms, and the other factors identified under the heading "Risk Factors" in the Company's annual report on Form 10-K filed on February 13, 2009, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. The company, for example, currently does not intend to provide updates regarding its exploration of strategic alternatives or to disclose developments or potential outcomes until and unless a definitive course of action is reached. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact:  Rob Skiba
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
2. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
3. Biopure Sues National Institutes of Health Official
4. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
5. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
6. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
7. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
8. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
9. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. Biopure Announces Closing of $14.9 Million Financing
11. Biopures Stock Symbol Reverts to BPUR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... AssureVest Insurance Group, ... is initiating a charity drive that will raise funds earmarked to purchase computers and ... Tayloe Elementary School. , “My school is in a low-income area and has more ...
(Date:2/12/2016)... ... 2016 , ... Donor Network West, the organ procurement organization that heals lives ... San Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific ... a more certain time frame for donor families for the recovery of organs. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... On Thursday, Feb. 11, 2016, surgeons at ... North Austin Medical Center successfully completed the first robotic ... Surgical System with Trumpf Medical,s advanced operating table, ... , M.D., colorectal surgeon at the Texas Institute for ... Motion technology, which seamlessly combines the da Vinci Xi ...
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: